选和描述针对布鲁顿的氨酸激酶的化小分子
Lauren E Kueffer1, David Yin-Wei Lin1, Neha Amatya1
1Roy J. Carver Department of Biochemistry, Biophysics, and Molecular Biology, Iowa State University, Ames, Iowa 50011, United States.
Biochemistry
|December 13, 2023
概括
研究人员发现了一种新的方法,以全osterically 准布鲁顿的氨酸激酶 (BTK). 这种方法为治疗B细胞淋巴瘤和X结合性血红细胞瘤 (XLA) 的现有活性位子抑制剂提供了一个有希望的替代方案.
科学领域:
- 生物化学和分子生物学
- 药物发现和开发 药物发现和开发
- 免疫学 免疫学 免疫学
背景情况:
- 布鲁顿的氨酸激酶 (BTK) 对B细胞的发育和生存至关重要,使其成为B细胞恶性瘤的关键标.
- 目前FDA批准的BTK抑制剂向活性部位,导致非向效应和获得耐药性.
- 链接到X的AGAMMAGLOBULINEMIA (XLA) 是BTK基因突变的结果,导致B细胞发育受损.
研究的目的:
- 探索BTK上的全位,用于药物开发,以实现更具体的向和克服耐药性.
- 识别和描述在非活性部位与BTK结合的小分子.
主要方法:
- 在BTK.上对非活跃网站口袋进行虚拟选.
- 使用生物化学和生物物理技术在体外鉴定识别的小分子的特征.
- 动力实验以评估作用模式和催化效率调制.
主要成果:
- 鉴定出了一系列的全性小分子,其中C2化合物显示出显著的前景.
- C2激活全长和多域BTK片段,但不激活隔离的激酶域,表明一个全性机制.
- C2通过降低Km和增加kcat来提高BTK的催化效率,并且可以激活BTK XLA突变.
结论:
- BTK可以有效地用小分子以全性向.
- 体BTK抑制是活性位点抑制的可行替代策略,有可能克服耐药性并减少非目标效应.
- 化合物C2可以作为基BTK向的原理证明.
相关概念视频
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.5K
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K